IQVIA Cancer Research SRL
IQVIA Cancer Research reported total assets of €1.07m at the end of the 2025 financial year (annual accounts filed with the NBB on 01 Jun 2026).
By total assets for 2025, IQVIA Cancer Research ranks in the top half of the 994 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of IQVIA Cancer Research shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets +255 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
IQVIA Cancer Research's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 01 Jun 2026
- Year ended 31 Dec 2024filed on 24 Jun 2025
- Year ended 31 Dec 2023filed on 10 Jul 2024
- Year ended 31 Dec 2022filed on 23 Aug 2023
- Year ended 31 Dec 2021filed on 25 Aug 2022
IQVIA Cancer Research's financial analysis
- Solvency-25.2%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of IQVIA Cancer Research
IQVIA Cancer Research's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0763.914.095
- VAT number
- BE0763914095
- Peppol
- Registered · 0208:0763914095 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 22 Feb 2021
- Registered office
- 1930 Zaventem
- Latest accounts
- 2025 · filed on 01 Jun 2026
- Activity
- Research and experimental development on other natural sciences and engineering (NACE 72109)
IQVIA Cancer Research (SRL) has been based in Zaventem since 2021, active in: research and experimental development on other natural sciences and engineering. For 2025, it reports a net profit of 38,859 € and equity of −269,667 €; its revenue is not published.
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to IQVIA Cancer Research
Companies in the same business, of comparable size and area, outside its group.
- Studiecentrum voor Kernenergie - Centre d'Etude de l'Energie Nucléaire Research and experimental development on natural sciences and engineering Auderghem · balance sheet €405.0m
- Recherche et Sante Research and experimental development on natural sciences and engineering Waterloo · balance sheet 75,174 €
- Oystershell Research and experimental development on natural sciences and engineering Merelbeke-Melle · balance sheet €32.7m
- Endymion Research and experimental development on natural sciences and engineering Ranst · balance sheet €1.31m
- Inokura Research and experimental development on natural sciences and engineering Liège · balance sheet €2.30m
- JCK Research and experimental development on natural sciences and engineering Montigny-le-Tilleul · balance sheet 1,364 €
- Alanine Research and experimental development on natural sciences and engineering Lasne · balance sheet 28,321 €
- BEX Research and experimental development on natural sciences and engineering Hasselt · balance sheet 738,139 €
Frequently asked questions about IQVIA Cancer Research
What is the revenue of IQVIA Cancer Research?
IQVIA Cancer Research files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of IQVIA Cancer Research?
In Belgium, the VAT number is the company number prefixed with BE: BE0763914095 for IQVIA Cancer Research, if the company is VAT-registered. Its company number (CBE) is 0763.914.095.
Where is the registered office of IQVIA Cancer Research?
According to the CBE register, the registered office of IQVIA Cancer Research is in 1930 Zaventem.
What is the equity of IQVIA Cancer Research?
At the close of the 2025 financial year, the equity of IQVIA Cancer Research amounts to -269,667 €, a solvency of -25.2% of total assets.
Who manages IQVIA Cancer Research?
The register lists 1 active mandates at IQVIA Cancer Research. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is IQVIA Cancer Research within its sector?
By total assets for 2025, IQVIA Cancer Research ranks in the top half of the 994 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year.
The full file of IQVIA Cancer Research
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →